Pharming Presents Research Findings at CIS Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy PHAR?
Source: Newsfilter
- Clinical Research Progress: Pharming showcased interim results from a long-term extension study of leniolisib for pediatric patients with APDS at the 2026 CIS Annual Meeting, indicating the drug's potential in improving immune function and offering new treatment options for patients.
- Clinical Trial Updates: Two Phase II clinical trials are currently underway to evaluate the safety and tolerability of leniolisib in patients with CVID and other immune dysregulation disorders, with results expected in the second half of this year, providing crucial data for further drug development.
- Diverse Research Topics: The meeting will also present clinical experiences using leniolisib in patients with CVID and CVID-like disorders, further revealing clinical characteristics of APDS and other primary immunodeficiencies, potentially advancing research in related fields.
- Company Strategic Direction: Pharming's Chief Medical Officer Anurag Relan noted that the data presented will enhance understanding of APDS and other immune dysregulations, reflecting the company's ongoing commitment to rare disease treatments, which may bolster investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHAR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHAR
Wall Street analysts forecast PHAR stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.000
Low
37.00
Averages
39.50
High
42.00
Current: 12.000
Low
37.00
Averages
39.50
High
42.00
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pharming Presents Research Findings at CIS Annual Meeting
- Clinical Research Progress: Pharming showcased interim results from a long-term extension study of leniolisib for pediatric patients with APDS at the 2026 CIS Annual Meeting, indicating the drug's potential in improving immune function and offering new treatment options for patients.
- Clinical Trial Updates: Two Phase II clinical trials are currently underway to evaluate the safety and tolerability of leniolisib in patients with CVID and other immune dysregulation disorders, with results expected in the second half of this year, providing crucial data for further drug development.
- Diverse Research Topics: The meeting will also present clinical experiences using leniolisib in patients with CVID and CVID-like disorders, further revealing clinical characteristics of APDS and other primary immunodeficiencies, potentially advancing research in related fields.
- Company Strategic Direction: Pharming's Chief Medical Officer Anurag Relan noted that the data presented will enhance understanding of APDS and other immune dysregulations, reflecting the company's ongoing commitment to rare disease treatments, which may bolster investor confidence.
See More
Pharming Releases 2026 Financial Guidance Amid Revenue Decline
- Revenue Decline: Pharming reported Q1 revenue of $72.4 million, an 8.5% year-over-year decrease that missed expectations by $19.67 million, primarily due to RUCONEST inventory drawdowns and exit from non-U.S. markets, indicating weakened market demand.
- Positive Cash Flow: Despite the revenue drop, Pharming achieved a positive operating cash flow of $2.0 million, reflecting the company's ongoing efforts in cost management and financial discipline, which helps maintain operational stability.
- Liquidity Position: As of the reporting period, Pharming had cash and marketable securities totaling $171.8 million, down $9.3 million from FY25, mainly due to a $12.3 million expense from DSP lease termination, indicating liquidity pressure.
- 2026 Financial Guidance: Pharming projects total revenues for FY 2026 to be between $405 million and $425 million, with an expected growth rate of 8% to 13%, and plans to invest $60 million in R&D to advance its pipeline, demonstrating confidence in future growth.
See More
Pharming to Present Multiple Studies at 2026 Clinical Immunology Society Annual Meeting
- Presentation Schedule: Pharming Group N.V. will deliver multiple scientific presentations at the Clinical Immunology Society Annual Meeting from May 6-9, 2026, in New Orleans, showcasing new data on Leniolisib in pediatric patients with activated phosphoinositide 3-kinase delta syndrome (APDS).
- Focus on Pediatric Study: One presentation will concentrate on interim safety and efficacy outcomes from an open-label long-term extension study in children aged 4-11, supporting Pharming's efforts to expand treatment access beyond the currently approved age group.
- Clinical Experience Data: Additional presentations will describe real-world and clinical experience data in Common Variable Immunodeficiency (CVID) and related immune dysregulation disorders, findings from the APDS-CHOIR registry, and caregiver and clinician-reported symptom assessments in pediatric APDS.
- Ongoing Study Design: Pharming and its academic collaborators will also present the design and baseline characteristics of an ongoing Phase 2 study evaluating Leniolisib in primary immunodeficiencies with enhanced PI3K pathway signaling.
See More
Pharming Group to Report Q1 2026 Financial Results on May 7
- Earnings Report Announcement: Pharming Group has confirmed that it will release its preliminary (unaudited) financial results for Q1 2026 and provide a business update on May 7, 2026, aimed at keeping investors and analysts informed of the latest company developments.
- Conference Call Details: Management will host a conference call and webcast on the same day at 13:30 CEST/07:30 EDT, requiring participants to register in advance to obtain dial-in information and a unique PIN, ensuring smooth access to the call.
- Webcast Availability: The webcast will be accessible on Pharming's website under the Investors/Financial Documents section, with a replay available shortly after the event, ensuring that investors who cannot participate live can still access the information.
- Company Background: Pharming Group is a global biopharmaceutical company dedicated to providing innovative medicines for patients with rare, life-threatening diseases, showcasing its expertise and market impact in the biopharmaceutical sector.
See More
Pharming Group Faces Securities Fraud Investigation
- Investigation Launched: The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Pharming Group, potentially filing a class action to protect investors' rights and recover losses.
- Stock Price Plunge: Pharming's American Depositary Receipt (ADR) plummeted by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026, resulting in significant losses for investors.
- FDA Regulatory Setback: The company faced a major setback as the FDA issued a Complete Response Letter (CRL) regarding the supplemental New Drug Application (sNDA) for Joenja® (leniolisib), citing concerns over potential underexposure in lower weight pediatric patients, which undermined investor confidence.
- Manufacturing Testing Issues: The CRL also identified issues with one of the analytical methods used for production batch testing, necessitating further data and clarification, exacerbating investor concerns about the company's future commercialization timeline.
See More
Pharming Group to Participate in Investor Conferences
- Conference Schedule: Pharming Group will participate in two significant investor conferences in April 2026, specifically the 25th Annual Needham Virtual Healthcare Conference on April 13 and the Van Lanschot Kempen Life Sciences Conference on April 15, showcasing its latest advancements in the biopharmaceutical sector.
- Executive Participation: CEO Fabrice Chouraqui and CMO Anurag Relan will present on April 13 at 08:45 am ET/14:45 CET, which is expected to attract investor attention and enhance the company's visibility within the industry.
- Live Webcast: The presentations will be available via live webcast and replay on Pharming's website under the
See More
Pharming Presents Research Findings at CIS Annual Meeting
- Clinical Research Progress: Pharming showcased interim results from a long-term extension study of leniolisib for pediatric patients with APDS at the 2026 CIS Annual Meeting, indicating the drug's potential in improving immune function and offering new treatment options for patients.
- Clinical Trial Updates: Two Phase II clinical trials are currently underway to evaluate the safety and tolerability of leniolisib in patients with CVID and other immune dysregulation disorders, with results expected in the second half of this year, providing crucial data for further drug development.
- Diverse Research Topics: The meeting will also present clinical experiences using leniolisib in patients with CVID and CVID-like disorders, further revealing clinical characteristics of APDS and other primary immunodeficiencies, potentially advancing research in related fields.
- Company Strategic Direction: Pharming's Chief Medical Officer Anurag Relan noted that the data presented will enhance understanding of APDS and other immune dysregulations, reflecting the company's ongoing commitment to rare disease treatments, which may bolster investor confidence.
See More
Pharming Releases 2026 Financial Guidance Amid Revenue Decline
- Revenue Decline: Pharming reported Q1 revenue of $72.4 million, an 8.5% year-over-year decrease that missed expectations by $19.67 million, primarily due to RUCONEST inventory drawdowns and exit from non-U.S. markets, indicating weakened market demand.
- Positive Cash Flow: Despite the revenue drop, Pharming achieved a positive operating cash flow of $2.0 million, reflecting the company's ongoing efforts in cost management and financial discipline, which helps maintain operational stability.
- Liquidity Position: As of the reporting period, Pharming had cash and marketable securities totaling $171.8 million, down $9.3 million from FY25, mainly due to a $12.3 million expense from DSP lease termination, indicating liquidity pressure.
- 2026 Financial Guidance: Pharming projects total revenues for FY 2026 to be between $405 million and $425 million, with an expected growth rate of 8% to 13%, and plans to invest $60 million in R&D to advance its pipeline, demonstrating confidence in future growth.
See More
Pharming to Present Multiple Studies at 2026 Clinical Immunology Society Annual Meeting
- Presentation Schedule: Pharming Group N.V. will deliver multiple scientific presentations at the Clinical Immunology Society Annual Meeting from May 6-9, 2026, in New Orleans, showcasing new data on Leniolisib in pediatric patients with activated phosphoinositide 3-kinase delta syndrome (APDS).
- Focus on Pediatric Study: One presentation will concentrate on interim safety and efficacy outcomes from an open-label long-term extension study in children aged 4-11, supporting Pharming's efforts to expand treatment access beyond the currently approved age group.
- Clinical Experience Data: Additional presentations will describe real-world and clinical experience data in Common Variable Immunodeficiency (CVID) and related immune dysregulation disorders, findings from the APDS-CHOIR registry, and caregiver and clinician-reported symptom assessments in pediatric APDS.
- Ongoing Study Design: Pharming and its academic collaborators will also present the design and baseline characteristics of an ongoing Phase 2 study evaluating Leniolisib in primary immunodeficiencies with enhanced PI3K pathway signaling.
See More
Pharming Group to Report Q1 2026 Financial Results on May 7
- Earnings Report Announcement: Pharming Group has confirmed that it will release its preliminary (unaudited) financial results for Q1 2026 and provide a business update on May 7, 2026, aimed at keeping investors and analysts informed of the latest company developments.
- Conference Call Details: Management will host a conference call and webcast on the same day at 13:30 CEST/07:30 EDT, requiring participants to register in advance to obtain dial-in information and a unique PIN, ensuring smooth access to the call.
- Webcast Availability: The webcast will be accessible on Pharming's website under the Investors/Financial Documents section, with a replay available shortly after the event, ensuring that investors who cannot participate live can still access the information.
- Company Background: Pharming Group is a global biopharmaceutical company dedicated to providing innovative medicines for patients with rare, life-threatening diseases, showcasing its expertise and market impact in the biopharmaceutical sector.
See More
Pharming Group Faces Securities Fraud Investigation
- Investigation Launched: The Portnoy Law Firm has initiated an investigation into possible securities fraud involving Pharming Group, potentially filing a class action to protect investors' rights and recover losses.
- Stock Price Plunge: Pharming's American Depositary Receipt (ADR) plummeted by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026, resulting in significant losses for investors.
- FDA Regulatory Setback: The company faced a major setback as the FDA issued a Complete Response Letter (CRL) regarding the supplemental New Drug Application (sNDA) for Joenja® (leniolisib), citing concerns over potential underexposure in lower weight pediatric patients, which undermined investor confidence.
- Manufacturing Testing Issues: The CRL also identified issues with one of the analytical methods used for production batch testing, necessitating further data and clarification, exacerbating investor concerns about the company's future commercialization timeline.
See More
Pharming Group to Participate in Investor Conferences
- Conference Schedule: Pharming Group will participate in two significant investor conferences in April 2026, specifically the 25th Annual Needham Virtual Healthcare Conference on April 13 and the Van Lanschot Kempen Life Sciences Conference on April 15, showcasing its latest advancements in the biopharmaceutical sector.
- Executive Participation: CEO Fabrice Chouraqui and CMO Anurag Relan will present on April 13 at 08:45 am ET/14:45 CET, which is expected to attract investor attention and enhance the company's visibility within the industry.
- Live Webcast: The presentations will be available via live webcast and replay on Pharming's website under the
See More
